Terazosin hydrochloride

Names

[ Name ]:
Terazosin hydrochloride

[Synonym ]:
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-
Terazosin
UNII:8L5014XET7
Vicard
Itrin
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone,hydrochloride
Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-
Urodie
[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)methanone
6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
MFCD00467965
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone

Biological Activity

[Description]:

Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

[Related Catalog]:

Research Areas >> Endocrinology

Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor

Research Areas >> Metabolic Disease

[Target]

α1-adrenoceptor[1]

[In Vitro]

Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells[1].

[In Vivo]

Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm[3].

[References]

[1]. Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.

[2]. Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.

[3]. Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
664.5±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₉H₂₆ClN₅O₄

[ Molecular Weight ]:
423.89

[ Flash Point ]:
355.7±34.3 °C

[ PSA ]:
103.04000

[ LogP ]:
-0.96

[ Appearance of Characters ]:
powder,white to off-white

[ Vapour Pressure ]:
0.0±2.0 mmHg at 25°C

[ Index of Refraction ]:
1.636

[ Storage condition ]:
Store at RT

[ Water Solubility ]:
H2O: 25 mg/mL

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TK8045000

CHEMICAL NAME :: Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahyd ro-2-furanyl)carbonyl )-, monohydrochloride

CAS REGISTRY NUMBER :: 63074-08-8

LAST UPDATED :: 199503

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C19-H25-N5-O4.Cl-H

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 277 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 7,435,1984 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4650 mg/kg/31D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Nutritional and Gross Metabolic - body temperature decrease Related to Chronic Data - death

REFERENCE :: DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 7,435,1984

Safety Information

[ Hazard Codes ]:
Xn,Xi

[ Risk Phrases ]:
22-36/37/38

[ Safety Phrases ]:
26-36

[ WGK Germany ]:
3

[ RTECS ]:
TK8044925

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.